

Antimicrobial Resistance History and Perspectives

REBEKAH M. MARTIN

LEARNING OBJECTIVES

1. Discuss the history of antibiotics and emergence of resistance.
2. Identify current antimicrobial-resistant threats and associated challenges.
3. Identify specific issues that must be addressed worldwide.

ABSTRACT

The Centers for Disease Control and Prevention (CDC) estimates that over 2 million individuals in the United States are infected by antibiotic-resistant organisms every year, and that these infections cause at least 23,000 deaths.¹ These statistics represent a significant threat to public health and require immediate action. To effectively combat infections caused by antibiotic-resistant organisms, several strategies must be employed. Important strategies include understanding microbial mechanisms of pathogenesis and resistance, development of novel antimicrobials and diagnostic tools, and prevention of infections. This series will explore the phenomenon of antimicrobial resistance (AMR) and the role that health care professionals play in identifying and combating these organisms.

ABBREVIATIONS: AMR - antimicrobial resistance, antimicrobial-resistant, CDC - Centers for Disease Control and Prevention.

INDEX TERMS: antibiotic resistance, antibiotics, antimicrobial resistance, antimicrobial susceptibility testing, resistance mechanisms.

Clin Lab Sci 2018;31(2):71–74

HISTORY OF ANTIBIOTICS AND EMERGENCE OF RESISTANCE

Antibiotics are defined as substances that have bactericidal or bacteriostatic effects. In other words, they are

Rebekah M. Martin, School of Health Sciences, Oakland University

Address for Correspondence: **Rebekah M. Martin**, Oakland University, rmartin2@oakland.edu

substances that can kill or slow the growth of bacteria. Antibiotics conventionally target 3 broad bacterial functions: cell wall synthesis, DNA replication, and RNA transcription or protein synthesis.² Bacteria are not the only microorganisms inhibited by therapeutics. Other microbes, such as viruses and fungi, can be treated using antimicrobial drugs. This series will focus primarily on antibiotics, but readers should be aware that the phenomenon of antimicrobial resistance (AMR) extends beyond bacterial resistance.³

The antibacterial properties of molds have been noted in the modern era since at least 1640 when John Parkinson, a London apothecary and the king's herbarist, suggested treating various conditions—including infections—with molds.⁴ In 1929, Alexander Fleming published his observations of bacterial inhibition by a "mould broth filtrate" from a *Penicillium* species.⁵ He called this filtrate *penicillin*. Over a decade later, the penicillin molecule was purified and its efficacy as an antibacterial therapeutic was tested in animal models.⁶ Isolated penicillin was subsequently tested in humans for toxicity⁷ and ultimately for effectiveness against infections.⁸ The remarkable nature of these findings was recognized in 1945 when the Nobel Prize in Medicine was awarded to 3 scientists, including Fleming, for their work in discovering penicillin and identifying its curative effects.⁹ Administration of penicillin as an antibacterial therapeutic became widely available following World War II. The miracle age of antibiotics had begun.

The discovery and application of penicillin to treat infectious diseases heralded a turning point in medical care. Penicillin and the scores of antibiotics identified since 1928 have saved the lives of millions of people worldwide.¹⁰ Prior to the introduction of antibiotics, a period often referred to as the *preantibiotic era*, a minor infection could—and frequently would—become life-threatening. Despite the seemingly miraculous properties of antibiotics, resistance to these drugs was found simultaneously with their discovery. In the same publication where he described penicillin's antibiotic properties, Fleming noted that some bacteria were not inhibited by penicillin.⁵ Prior to the widespread use of penicillin, *Staphylococcus aureus*, which was identified by Fleming as susceptible to this drug, developed penicillin resistance.¹ Since then, introduction of various antibiotics is often quickly followed by resistance to that antibiotic.

Compounding this issue is the relative lack of novel antibiotics being introduced.¹ In other words, bacteria are evolving resistance more quickly than the medical field can develop new antibiotics to treat them. Widespread antibiotic resistance, coupled with a lack of novel antibiotics, led

the World Health Organization to project the imminence of a postantibiotic era in 2014, where once again minor infections would become potentially deadly.^{11,12}

An important factor contributing to the emergence of antibiotic resistance is the misuse of antibiotics.¹ Misuse includes overprescription of antibiotics as well as overuse in the agricultural sector. It has been suggested that up to 50% of antibiotics prescribed for humans are unnecessary.¹ Similarly, use of antibiotics in consumed animal products has been linked to antibiotic-resistant bacteria in humans, and represents a threat to human health.¹³ Therefore, antimicrobial stewardship is often aimed at reducing the misuse of antibiotics in both health care and agriculture.¹

CURRENT ANTIMICROBIAL THREATS AND ASSOCIATED CHALLENGES

As an indicator of how serious the issue of antibiotic resistance has become, in 2013 the Centers for Disease Control and Prevention (CDC) compiled their first-ever threat report detailing antibiotic resistance in the United States and proposing strategies to address these concerns.¹ The report provides information on specific bacteria and one fungus that are emerging as concerning, serious, and urgent threats to public health. At the top of the CDC's 2013 threat list are 3 organisms that pose an urgent threat to public health: *Clostridium difficile*, recently reclassified as *Clostridioides difficile*;¹⁴ carbapenem-resistant *Enterobacteriaceae* (CRE); and drug-resistant *Neisseria gonorrhoeae*. Since 2013, there has been an increase in resistance to drugs of last resort worldwide in both CRE and *N. gonorrhoeae*.¹⁵⁻¹⁷ The overarching concern with antibiotic-resistant organisms is that there will soon be widespread pan-resistance. The emergence of resistance to drugs of last resort indicates that this is a realistic concern. In fact, pan-resistant *Klebsiella pneumoniae* has already been isolated in the United States.¹⁷

Along with representing a significant threat to public health, AMR infections further present a substantial economic burden in the United States. Per-person cost estimates in the United States for those infected by AMR organisms ranges from \$18,588 to \$29,069, and total economic burden estimates in the United States are as high as \$20 billion per year in total health care costs.¹⁸ AMR infections are also frequently identified as health-care-associated infections, which represent an additional financial burden. The projected global economic impact estimates will be discussed later in this series.

In attempting to track, treat, and prevent infections caused by AMR organisms, understanding how these organisms are transmitted among individuals is important. Several routes of transmission have been identified for AMR organisms. In a health care setting, organisms are frequently spread from patient to patient by health care workers' hands.¹⁹ Therefore, improving adherence to hand

hygiene protocols can lead to decreased organism prevalence over time.²⁰ Medical equipment is also a frequent route of transmission. For example, the 2015 outbreak of carbapenem-resistant *K. pneumoniae* at a University of California, Los Angeles medical center was facilitated by contaminated duodenoscopes.²¹ Similarly, various hospital surfaces are also often cited as routes of transmission. A recent study identified hospital drains as a reservoir for antibiotic-resistant bacteria.²² Identification of transmission routes opens the door for intervention prior to transmission, which can decrease the prevalence of AMR organisms and ultimately prevent disease.²⁰

Recognition of how organisms acquire resistance mechanisms is vital to combating the spread of resistance. In bacteria, antibiotic-resistant genes can encode intrinsic resistance in a species, such as *Enterococci* species' intrinsic resistance to cephalosporins²³ or intrinsic resistance to ampicillin within *Klebsiella* species.²⁴ Bacteria can also acquire resistance to various antibiotics. Plasmid-mediated antibiotic resistance loci are of primary concern among acquired mechanisms of resistance because they are easily transmissible among multiple bacterial species. This means that previously susceptible pathogens can easily become resistant.²⁵ Of recent concern is the plasmid-mediated *mcr-1* gene that was first identified in Gram-negative organisms in China,¹⁵ but it was recently identified in *Escherichia coli* isolated from a human patient in the United States.²⁶ The *mcr-1* gene is of particular concern because it encodes resistance to colistin, a polymyxin drug of last resort, indicating that easy transmission among multidrug-resistant bacteria could lead to pan-resistance. Mechanisms of antibiotic resistance will be discussed in depth later in this series.

Once a patient becomes infected, laboratory testing to identify AMR organisms and their resistance patterns is an integral part of treatment. Accurate testing and reporting play an important role in antimicrobial stewardship as well, allowing physicians to administer appropriate antibiotics.²⁷ As the landscape of resistance continues to evolve, the methods and technologies used to identify organisms and resistance patterns must also evolve.

SERIES FOCUS

As microorganisms continue to evolve novel mechanisms of resistance and exchange mobile genetic elements amongst themselves, the medical field must discover new ways to combat them. The arms race between humanity and AMR organisms represents a striking example of the Red Queen Hypothesis, which suggests that organisms must continuously evolve and adapt amidst the pressures of other organisms' evolution to simply maintain the status quo.²⁸ Essentially, scientists are running as fast as they can in order to stay in the exact same place.

Ultimately, our goal is to outrun and outfight these microorganisms. To that end, the CDC has proposed 4 core

actions to help combat antibiotic resistance in the United States: 1) prevention of both infections and the spread of AMR; 2) tracking resistance patterns, both domestically and globally; 3) improving antibiotic stewardship; and 4) development of new antibiotics and novel diagnostic tests.¹ The articles in this series will discuss various aspects of several of these core actions and how they contribute to understanding and combating infections caused by AMR organisms. This series seeks to provide readers with a broad understanding of the tools and methods currently in place to fight these infections as well as an introduction to the development of new tools and methods. Readers will also receive an overview of challenges frequently encountered in this “war against bugs.” Before effectively combating AMR organisms, scientists must understand how they are able to evade current therapies. Knowledge of both the mechanisms of antimicrobial therapies and mechanisms of resistance employed by organisms are vital to this understanding. Furthermore, as resistance spreads, development of novel antimicrobials is necessary. These issues will be discussed in the second article of this series, *Antibiotics and Bacterial Mechanisms of Resistance*. Accurate antimicrobial-susceptibility testing is imperative for effective treatment of infections and reflects the importance of the role of the clinical microbiology team in combating AMR organisms.

Current antimicrobial susceptibility testing methods and challenges, as well as the future of testing, are addressed in the third article, *Antimicrobial Susceptibility Testing Paradigms: Current Status and Future Directions*. Finally, it is important to remember that AMR is a global problem and requires a global solution. Successful reduction in the spread of resistance involves the efforts of scientists, physicians, the agricultural sector, politicians, and regulatory agencies worldwide. Multiple issues have contributed to the emergence of AMR, which suggests that a multifaceted approach will be required to combat AMR organisms. AMR as a global, multilayered issue will be discussed in the final article of this series, *Globalization and Antimicrobial Resistance: A Moving Target*.

REFERENCES

- Centers for Disease Control and Prevention (CDC). Antibiotic resistant threats in the United States, 2013. CDC, US Dept of Health and Human Services; 2014.
- Clatworthy AE, Pierson E, Hung DT. Targeting virulence: a new paradigm for antimicrobial therapy. *Nat Chem Biol*. 2007;3(9):541–548. doi: [10.1038/nchembio.2007.24](https://doi.org/10.1038/nchembio.2007.24)
- Arendrup MC. Update on antifungal resistance in *Aspergillus* and *Candida*. *Clin Microbiol Infect*. 2014;20(suppl 6):42–48. doi: [10.1111/1469-0691.12513](https://doi.org/10.1111/1469-0691.12513)
- Parkinson J. *Theatrum Botanicum*. 1640.
- Fleming A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of *B. influenzae*. *Br J Exp Pathol*. 1929;10(3):226–236.
- Chain E, Florey HW, Gardner AD, et al. Penicillin as a chemotherapeutic agent. *Lancet*. 1940;236(6104):226–228. doi: [10.1016/S0140-6736\(01\)08728-1](https://doi.org/10.1016/S0140-6736(01)08728-1)
- Dawson MH, Hobby GL, Meyer K, et al. Penicillin as a chemotherapeutic agent. *Ann Intern Med*. 1943;19(5):707–717. doi: [10.7326/0003-4819-19-5-707](https://doi.org/10.7326/0003-4819-19-5-707)
- Florey ME, Adelaide MB, Florey HW, Adelaide MB. General and local administration of penicillin. *Lancet*. 1943;241(6239):387–397. doi: [10.1016/S0140-6736\(00\)41962-8](https://doi.org/10.1016/S0140-6736(00)41962-8)
- The Nobel Prize Foundation. *The Nobel Prize in Physiology or Medicine 1945*. 1945.
- Infectious Diseases Society of America (IDSA). IDSA antibiotic resistance infographic 2016 final. Infographic presented at: US Stakeholder Forum on Antimicrobial Resistance; 2016.
- World Health Organization (WHO). WHO's first global report on antibiotic resistance reveals serious, worldwide threat to public health. 2014.
- Reardon S. WHO warns against ‘post-antibiotic’ era. *Nature*. 2014. doi: [10.1038/nature.2014.15135](https://doi.org/10.1038/nature.2014.15135)
- Landers TF, Cohen B, Wittum TE, Larson EL. A review of antibiotic use in food animals: perspective, policy, and potential. *Public Health Rep*. 2012;127(1):4–22. doi: [10.1177/003335491212700103](https://doi.org/10.1177/003335491212700103)
- Lawson PA, Citron DM, Tyrrell KL, Finegold SM. Re-classification of *Clostridium difficile* as *Clostridioides difficile* (Hall and O’Toole 1935) Prévot 1938. *Anaerobe*. 2016;40:95–99. doi: [10.1016/j.anaerobe.2016.06.008](https://doi.org/10.1016/j.anaerobe.2016.06.008)
- Liu Y-Y, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. *Lancet Infect Dis*. 2016;16(2):161–168. doi: [10.1016/S1473-3099\(15\)00424-7](https://doi.org/10.1016/S1473-3099(15)00424-7)
- Wi T, Lahra MM, Ndowa F, et al. Antimicrobial resistance in *Neisseria gonorrhoeae*: global surveillance and a call for international collaborative action. *PLoS Med*. 2017;14(7):e1002344. doi: [10.1371/journal.pmed.1002344](https://doi.org/10.1371/journal.pmed.1002344)
- Chen L, Todd R, Kiehlbauch J, Walters M, Kallen A. Notes from the field: pan-resistant New Delhi metallo-beta-lactamase-producing *Klebsiella pneumoniae* - Washoe County, Nevada, 2016. *MMWR Morb Mortal Wkly Rep*. 2017;66(1):33. doi: [10.15585/mmwr.mm6601a7](https://doi.org/10.15585/mmwr.mm6601a7)
- Golkar Z, Bagasra O, Pace DG. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis. *J Infect Dev Ctries*. 2014;8(2):129–136. doi: [10.3855/jidc.3573](https://doi.org/10.3855/jidc.3573)
- Mulvey MR, Simor AE. Antimicrobial resistance in hospitals: how concerned should we be? *CMAJ*. 2009;180(4):408–415. doi: [10.1503/cmaj.080239](https://doi.org/10.1503/cmaj.080239)
- D’Agata EMC, Horn MA, Ruan S, Webb GF, Wares JR. Efficacy of infection control interventions in reducing the spread of multidrug-resistant organisms in the hospital setting. *PLoS One*. 2012;7(2):e30170. doi: [10.1371/journal.pone.0030170](https://doi.org/10.1371/journal.pone.0030170)
- Humphries RM, Yang S, Kim S, et al. Duodenoscope-related outbreak of a carbapenem-resistant *Klebsiella pneumoniae* identified using advanced molecular diagnostics. *Clin Infect Dis*. 2017;65(7):1159–1166. doi: [10.1093/cid/cix527](https://doi.org/10.1093/cid/cix527)
- Weingarten RA, Johnson RC, Conlan S, et al; NISC Comparative Sequencing Program. Genomic analysis of hospital plumbing reveals diverse reservoir of bacterial plasmids conferring carbapenem resistance. *MBio*. 2018;9(1):e02011–e02017. doi: [10.1128/mBio.02011-17](https://doi.org/10.1128/mBio.02011-17)
- Murray BE. The life and times of the *Enterococcus*. *Clin Microbiol Rev*. 1990;3(1):46–65. doi: [10.1128/CMR.3.1.46](https://doi.org/10.1128/CMR.3.1.46)
- Babini GS, Livermore DM. Are SHV β -lactamases universal in *Klebsiella pneumoniae*? *Antimicrob Agents Chemother*. 2000;44(8):2230. doi: [10.1128/AAC.44.8.2230-2230.2000](https://doi.org/10.1128/AAC.44.8.2230-2230.2000)
- Andersson DI, Hughes D. Selection and transmission of antibiotic-resistant bacteria. *Microbiol Spectr*. 2017;5(4):5.4.12. doi: [10.1128/microbiolspec.MTBP-0013-2016](https://doi.org/10.1128/microbiolspec.MTBP-0013-2016)
- McGann P, Snesrud E, Maybank R, et al. *Escherichia coli* harboring mcr-1 and blaCTX-M on a novel IncF Plasmid: first report of

- mcr-1 in the United States. *Antimicrob Agents Chemother.* 2016;60(7):4420–4421. doi: [10.1128/AAC.01103-16](https://doi.org/10.1128/AAC.01103-16)
27. Morency-Potvin P, Schwartz DN, Weinstein RA. Antimicrobial stewardship: how the microbiology laboratory can right the ship. *Clin Microbiol Rev.* 2016;30(1):381–407. doi: [10.1128/CMR.00066-16](https://doi.org/10.1128/CMR.00066-16)
28. Van Valen L. A new evolutionary law. *Evol Theory.* 1973;1:1–30.